Cargando…
Almonertinib-induced interstitial lung disease: A case report
RATIONALE: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have elicited favorable anti-tumor activity in non-small cell lung cancer especially the lung adenocarcinoma. Interstitial lung disease (ILD) is 1 of the fatal side effects of EGFR-TKIs. However, such type of side eff...
Autores principales: | Jiang, Ting, Luo, Yiyang, Wang, Binbin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837903/ https://www.ncbi.nlm.nih.gov/pubmed/33546082 http://dx.doi.org/10.1097/MD.0000000000024393 |
Ejemplares similares
-
Almonertinib-induced interstitial lung disease in a lung adenocarcinoma patient complicated with interstitial lung abnormality
por: Zhou, Qian, et al.
Publicado: (2023) -
Successful administration of low-dose almonertinib in a patient with lung adenocarcinoma after osimertinib-induced interstitial lung disease: a case report and literature review
por: Chen, Wenyan, et al.
Publicado: (2022) -
In vivo evaluation of the pharmacokinetic interactions between almonertinib and rivaroxaban, almonertinib and apixaban
por: Wang, Zhi, et al.
Publicado: (2023) -
Platinum-doublet chemotherapy followed by pembrolizumab therapy for lung cancer with lymphangitis carcinomatosa mimicking interstitial pneumonitis: A case report
por: Yamasaki, Masahiro, et al.
Publicado: (2019) -
Effective treatment in lung adenocarcinoma patient with brain metastases harboring novel CLHC1/RNT4 intergenic region- ALK fusion: A case report
por: Xia, Huanling, et al.
Publicado: (2022)